Jillian M. Schurr
Katten Muchin Rosenman LLPGeneral
Experience6 yrs
Elite Ratings
--
Practice Areas
Biotech (25 cases)
Chemical (2 cases)
Reexam/Aband. (2 cases)
Ratings
Experience
Grade
Trend
DCT
L1
E
PTAB
--
--
--
CAFC
--
--
--
Cases
Case # | Court | Caption | Filed | Represent |
|---|---|---|---|---|
| 1:25-CV-00024 | Salix Pharma Inc v. Mylan Pharma Inc | 03/26/25 | Challenger | |
| 3:25-CV-01895 | Opus Genetics Inc v. Sandoz Inc | 03/14/25 | Patent Owner | |
| 1:23-CV-00759 | Mitsubishi Tanabe Pharma Corp v. Cipla USA Inc | 07/12/23 | Challenger | |
| 2:22-CV-00216 | UCB Inc v. Mylan Tech Inc | 12/12/22 | Challenger | |
| 1:22-CV-01423 | AbbVie Inc v. Alkem Laboratories Ltd | 10/27/22 | Challenger | |
| 1:22-CV-01365 | Merck KGaA v. Hopewell Pharma Ventures Inc | 10/17/22 | Challenger | |
| 1:21-MD-03017 | In re: Xarelto (Rivaroxaban) ('310) Patent Litigation | 12/10/21 | ||
| 1:21-CV-01408 | Neurocrine Biosciences Inc v. Lupin Ltd | 10/01/21 | ||
| 3:21-CV-15137 | Janssen Research Development LLC v. Mylan | 08/11/21 | Challenger | |
| 1:21-CV-00314 | Bayer Pharma AG v. Lupin Ltd | 03/01/21 |